|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 236.70 USD | -1.22% |
|
-4.65% | +14.46% |
| 05:01pm | Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment | MT |
| 04:46pm | Oil Shock Meets Job Shock |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 20.88B | 17.94B | 35.15B | 14.07B | 26.8B | |||||
Depreciation & Amortization - CF | 2.69B | 2.67B | 2.6B | 2.84B | 2.9B | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 4.7B | 4.3B | 4.5B | 4.5B | 4.6B | |||||
Depreciation & Amortization, Total | 7.39B | 6.97B | 7.1B | 7.34B | 7.5B | |||||
(Gain) Loss From Sale Of Asset | -617M | -380M | -117M | -226M | -263M | |||||
Asset Writedown & Restructuring Costs | 989M | 1.22B | 1.78B | 2.25B | 313M | |||||
Provision for Credit Losses | -48M | - | - | - | - | |||||
Stock-Based Compensation (CF) | 1.14B | 1.14B | 1.16B | 1.18B | 1.35B | |||||
Provision and Write-off of Bad Debts | - | -17M | - | 11M | -1M | |||||
Net Cash From Discontinued Operations | - | - | -20.6B | - | - | |||||
Other Operating Activities, Total | -2.08B | -1.66B | -4.19B | -2.18B | 1.54B | |||||
Change In Accounts Receivable | -2.4B | -1.29B | -624M | -406M | -1.78B | |||||
Change In Inventories | -1.25B | -2.53B | -1.32B | -1.13B | -1.45B | |||||
Change In Accounts Payable | 2.44B | 1.1B | 2.35B | 1.62B | 2.38B | |||||
Change in Other Net Operating Assets | -3.02B | -1.29B | 2.11B | 1.75B | -11.86B | |||||
Cash from Operations | 23.41B | 21.19B | 22.79B | 24.27B | 24.53B | |||||
Capital Expenditure | -3.65B | -4.01B | -5.01B | -4.42B | -4.83B | |||||
Sale of Property, Plant, and Equipment | 711M | 543M | 358M | 675M | 720M | |||||
Cash Acquisitions | -60M | -17.65B | - | -15.15B | -17.54B | |||||
Divestitures | - | - | - | - | - | |||||
Sale (Purchase) of Intangible assets | - | - | - | -1.78B | -385M | |||||
Investment in Marketable and Equity Securities, Total | -5.39B | 9.22B | 8.48B | 736M | 741M | |||||
Other Investing Activities, Total | -294M | -478M | -2.95B | 1.34B | -2.29B | |||||
Cash from Investing | -8.68B | -12.37B | 878M | -18.6B | -23.59B | |||||
Short Term Debt Issued, Total | 2B | 16.13B | 13.74B | 15.28B | 14.59B | |||||
Long-Term Debt Issued, Total | 5M | 2M | - | 6.66B | 9.14B | |||||
Total Debt Issued | 2B | 16.14B | 13.74B | 21.94B | 23.72B | |||||
Short Term Debt Repaid, Total | -1.19B | -6.55B | -22.97B | -9.46B | -12.33B | |||||
Long-Term Debt Repaid, Total | -1.8B | -2.13B | -1.55B | -1.45B | -1.76B | |||||
Total Debt Repaid | -2.99B | -8.68B | -24.52B | -10.92B | -14.09B | |||||
Issuance of Common Stock | 1.04B | 1.33B | 1.09B | 838M | 3.42B | |||||
Repurchase of Common Stock | -3.46B | -6.04B | -5.05B | -2.43B | -5.95B | |||||
Common Dividends Paid | -11.03B | -11.68B | -11.77B | -11.82B | -12.38B | |||||
Common & Preferred Stock Dividends Paid | -11.03B | -11.68B | -11.77B | -11.82B | -12.38B | |||||
Other Financing Activities, Total | 395M | 65M | 10.69B | -736M | -260M | |||||
Cash from Financing | -14.05B | -8.87B | -15.82B | -3.13B | -5.54B | |||||
Foreign Exchange Rate Adjustments | -178M | -312M | -112M | -289M | 201M | |||||
Net Change in Cash | 502M | -360M | 7.73B | 2.25B | -4.4B | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 941M | 933M | 1.77B | 1.91B | 1.86B | |||||
Cash Income Tax Paid (Refund) | 4.77B | 5.22B | 8.57B | 6.71B | 6.54B | |||||
Levered Free Cash Flow | 18.82B | 19.19B | 19.79B | 16.67B | 16.63B | |||||
Unlevered Free Cash Flow | 18.93B | 19.36B | 20.27B | 17.14B | 17.24B | |||||
Change In Net Working Capital | 1.72B | 833M | -2.23B | -704M | 2.86B | |||||
Net Debt Issued / Repaid | -990M | 7.45B | -10.78B | 11.02B | 9.64B |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















